Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 188 points (1.1%) at 17,006 as of Tuesday, Oct. 28, 2014, 4:20 PM ET. The NYSE advances/declines ratio sits at 2,601 issues advancing vs. 503 declining with 115 unchanged.

The Health Services industry as a whole closed the day up 1.6% versus the S&P 500, which was up 1.2%. Top gainers within the Health Services industry included

SunLink Health Systems

(

SSY

), up 3.9%,

American Caresource Holdings

(

ANCI

), up 12.9%,

Vision-Sciences

(

VSCI

), up 1.5%,

BSD Medical

(

BSDM

), up 4.3% and

BioLife Solutions

(

BLFS

), up 1.9%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

BioLife Solutions

(

BLFS

) is one of the companies that pushed the Health Services industry higher today. BioLife Solutions was up $0.04 (1.9%) to $2.19 on light volume. Throughout the day, 8,549 shares of BioLife Solutions exchanged hands as compared to its average daily volume of 32,000 shares. The stock ranged in a price between $2.11-$2.20 after having opened the day at $2.20 as compared to the previous trading day's close of $2.15.

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. BioLife Solutions has a market cap of $25.4 million and is part of the health care sector. Shares are unchanged year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate BioLife Solutions a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates BioLife Solutions as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

Highlights from TheStreet Ratings analysis on BLFS go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 212.4% when compared to the same quarter one year ago, falling from -$0.28 million to -$0.88 million.
  • Net operating cash flow has significantly decreased to -$0.87 million or 524.27% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • BIOLIFE SOLUTIONS INC's earnings have gone downhill when comparing its most recently reported quarter with the same quarter a year earlier. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, BIOLIFE SOLUTIONS INC continued to lose money by earning -$0.14 versus -$0.42 in the prior year. For the next year, the market is expecting a contraction of 85.7% in earnings (-$0.26 versus -$0.14).
  • This stock's share value has moved by only 86.35% over the past year. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The revenue fell significantly faster than the industry average of 3.2%. Since the same quarter one year prior, revenues fell by 48.0%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

You can view the full analysis from the report here:

BioLife Solutions Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Vision-Sciences

(

VSCI

) was up $0.01 (1.5%) to $0.97 on light volume. Throughout the day, 20,007 shares of Vision-Sciences exchanged hands as compared to its average daily volume of 37,900 shares. The stock ranged in a price between $0.91-$0.97 after having opened the day at $0.91 as compared to the previous trading day's close of $0.96.

Vision-Sciences, Inc., through its subsidiaries, designs, develops, manufactures, and markets endoscopy products. It operates through Medical and Industrial segments. Vision-Sciences has a market cap of $46.2 million and is part of the health care sector. Shares are down 3.0% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Vision-Sciences a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Vision-Sciences as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on VSCI go as follows:

  • In its most recent trading session, VSCI has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • 35.05% is the gross profit margin for VISION-SCIENCES INC which we consider to be strong. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -52.69% is in-line with the industry average.
  • Net operating cash flow has increased to -$0.95 million or 33.40% when compared to the same quarter last year. In addition, VISION-SCIENCES INC has also vastly surpassed the industry average cash flow growth rate of -50.70%.
  • VISION-SCIENCES INC has improved earnings per share by 20.0% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. During the past fiscal year, VISION-SCIENCES INC continued to lose money by earning -$0.16 versus -$0.22 in the prior year.
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Health Care Equipment & Supplies industry average. The net income increased by 18.8% when compared to the same quarter one year prior, going from -$2.43 million to -$1.98 million.

You can view the full analysis from the report here:

Vision-Sciences Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

American Caresource Holdings

(

ANCI

) was another company that pushed the Health Services industry higher today. American Caresource Holdings was up $0.35 (12.9%) to $3.06 on average volume. Throughout the day, 10,246 shares of American Caresource Holdings exchanged hands as compared to its average daily volume of 10,900 shares. The stock ranged in a price between $2.73-$3.06 after having opened the day at $2.73 as compared to the previous trading day's close of $2.71.

American CareSource Holdings, Inc. provides access to a network of ancillary healthcare service providers in the United States. American Caresource Holdings has a market cap of $19.4 million and is part of the health care sector. Shares are up 76.2% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate American Caresource Holdings a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates American Caresource Holdings as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow.

Highlights from TheStreet Ratings analysis on ANCI go as follows:

  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Health Care Providers & Services industry and the overall market, AMERICAN CARESOURCE HLDGS's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has decreased to -$1.24 million or 24.57% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • AMERICAN CARESOURCE HLDGS has improved earnings per share by 19.2% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, AMERICAN CARESOURCE HLDGS reported poor results of -$0.66 versus -$0.54 in the prior year.
  • ANCI, with its decline in revenue, underperformed when compared the industry average of 19.5%. Since the same quarter one year prior, revenues slightly dropped by 7.3%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • ANCI's debt-to-equity ratio is very low at 0.18 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, ANCI has a quick ratio of 1.54, which demonstrates the ability of the company to cover short-term liquidity needs.

You can view the full analysis from the report here:

American Caresource Holdings Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.